Celltrion seeks new drug partners at Milan trade show
Celltrion says it will use the CPHI Worldwide trade show in Milan to seek partners for new drug development, contract manufacturing, and supply chains. The company aims to broaden its cooperation in overseas raw material sourcing and CDMO (contract development and manufacturing organization) deals, while focusing on oncology, obesity/metabolic, and autoimmune disease programs as early results emerge.
What is happening at the show
Celltrion plans to present at CPHI Worldwide in Milan on Oct. 6-8 to find partners for new drug projects, manufacturing, and supply chains. The trade event gathers thousands of industry professionals from many countries, making it a key place for collaborations and deal talks. Celltrion says its booth will highlight its drug development and manufacturing capabilities and its aim to build a stable global supply chain.
Key facts you should know
- CPHI Worldwide is a global pharmaceutical trade show in Milan, expected to draw about 60,000 professionals from around 170 countries.
- Celltrion is a company known for biosimilars—lower-cost versions of complex biologic drugs whose patents have expired.
- The company is targeting new drug candidates in three areas: oncology (cancer), obesity/metabolic diseases, and autoimmune diseases.
- In addition to new drugs, Celltrion wants more contract manufacturing and raw material partnerships abroad (CDMO-related work).
Who could be affected
When a biopharma company expands its partnerships and manufacturing options, potential effects include more collaboration opportunities for suppliers and contract manufacturers, as well as potential changes in the supply chain for biologic drugs. The announcement is a strategic business move; it does not itself imply immediate patient impact until partnerships translate into approved medicines or accelerated development timelines.
Practical next steps for readers
- Watch for company disclosures on any new CDMO partnerships or announced drug candidates following the Milan event.
- Note that CDMO talks are about development and manufacturing services rather than immediate patient therapies.
- Businesses in relevant sectors (raw materials, contract manufacturing) may monitor Celltrion’s supplier lists and press releases for potential collaboration opportunities.
- For readers affected indirectly, keep an eye on regulatory milestones that could lead to new medications supported by expanded manufacturing capacity.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- koreatimes.co.kr — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.